{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:52:33Z","timestamp":1789707153901,"version":"4.0.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.yebeh.2020.107261","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T17:54:44Z","timestamp":1593798884000},"page":"107261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Polypharmacy in patients with epilepsy: A nationally representative cross-sectional study"],"prefix":"10.1016","volume":"111","author":[{"given":"Samuel W.","family":"Terman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole E.","family":"Aubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe E.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donovan T.","family":"Maust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Betjemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia M.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2020.107261_bb0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.seizure.2016.11.013","article-title":"Physical and mental health comorbidities of epilepsy: population-based cross-sectional analysis of 1.5 million people in Scotland","volume":"45","author":"Weatherburn","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.107261_bb0010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cger.2012.01.001","article-title":"Factors leading to excessive polypharmacy","volume":"28","author":"Hovstadius","year":"2012","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.yebeh.2020.107261_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043617","article-title":"Inappropriateness of medication prescriptions to elderly patients in the primary care setting: a systematic review","volume":"7","author":"Opondo","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.yebeh.2020.107261_bb0020","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/archinte.161.13.1629","article-title":"Risk factors for adverse drug events among nursing home residents","volume":"161","author":"Field","year":"2001","journal-title":"Arch Int Med"},{"key":"10.1016\/j.yebeh.2020.107261_bb0025","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/jgs.14682","article-title":"Clinical outcomes associated with medication regimen complexity in older people: a systematic review","volume":"65","author":"Wimmer","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.yebeh.2020.107261_bb0030","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/jgs.15317","article-title":"Associations between polypharmacy and cognitive and physical capability: a British Birth Cohort Study","volume":"66","author":"Rawle","year":"2018","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.yebeh.2020.107261_bb0035","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jclinepi.2012.02.018","article-title":"Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes","volume":"65","author":"Gnjidic","year":"2012","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.yebeh.2020.107261_bb0040","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","article-title":"Emergency hospitalization for adverse drug events in older Americans","volume":"365","author":"Budnitz","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2020.107261_bb0045","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1001\/jama.2016.16201","article-title":"US emergency department visits for outpatient adverse drug events, 2013\u20132014","volume":"316","author":"Shehab","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2020.107261_bb0050","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/jamaneurol.2018.0333","article-title":"Risk of unnatural mortality in people with epilepsy","volume":"75","author":"Gorton","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2020.107261_bb0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.yebeh.2013.11.028","article-title":"Is antiepileptic drug withdrawal status related to quality of life in seizure-free adult patients with epilepsy?","volume":"31","author":"Zou","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107261_bb0060","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.yebeh.2016.01.033","article-title":"Analgesic opioid use in a health-insured epilepsy population during 2012","volume":"57","author":"Wilner","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107261_bb0065","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.yebeh.2014.08.131","article-title":"Diagnoses, procedures, drug utilization, comorbidities, and cost of health care for people with epilepsy in 2012","volume":"41","author":"Wilner","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107261_bb0070","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.seizure.2011.06.015","article-title":"Use and costs of concomitant medicines in epileptic patients in Poland: a 12-month prospective multicentre study","volume":"20","author":"Majkowska-Zwoli\u0144ska","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.107261_bb0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.eplepsyres.2017.11.001","article-title":"Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: a pharmacoepidemiological study of CNS-active drugs in Norway, 2004\u20132015","volume":"139","author":"Baftiu","year":"2018","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2020.107261_bb0080","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/j.1532-5415.2005.53523.x","article-title":"Unnecessary drug use in frail older people at hospital discharge","volume":"53","author":"Hajjar","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.yebeh.2020.107261_bb0085","first-page":"1","article-title":"What is polypharmacy?","author":"Masnoon","year":"2017","journal-title":"A systematic review of definitions"},{"key":"10.1016\/j.yebeh.2020.107261_bb0090","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/aje\/kwj124","article-title":"Trends in the prevalence, awareness, treatment, and control of cardiovascular disease risk factors among noninstitutionalized patients with a history of myocardial infarction and stroke","volume":"163","author":"Muntner","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.yebeh.2020.107261_bb0095","author":"National Health and Nutrition Examination Survey: Analytic Guidelines"},{"key":"10.1016\/j.yebeh.2020.107261_bb0100","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 Updated AGS Beers Criteria \u00ae for potentially inappropriate medication use in older adults","volume":"67","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.yebeh.2020.107261_bb0105","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/jamainternmed.2016.9225","article-title":"Trends in central nervous system-active polypharmacy among older adults seen in outpatient care in the United States","volume":"177","author":"Maust","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.yebeh.2020.107261_bb0110","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1592\/phco.20.19.1423.34854","article-title":"Tramadol and seizures: a surveillance study in a managed care population","volume":"20","author":"Gardner","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.yebeh.2020.107261_bb0115","doi-asserted-by":"crossref","first-page":"1382.e1","DOI":"10.1016\/j.amjmed.2018.04.025","article-title":"Tramadol: understanding the risk of serotonin syndrome and seizures","volume":"131","author":"Hassamal","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.yebeh.2020.107261_bb0120","first-page":"106","article-title":"15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL","volume":"7","author":"Fava","year":"2005","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.yebeh.2020.107261_bb0125","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2165\/00003495-200868050-00011","article-title":"Bupropion: a review of its use in the management of major depressive disorder","volume":"68","author":"Dhillon","year":"2008","journal-title":"Drugs and Aging"},{"key":"10.1016\/j.yebeh.2020.107261_bb0130","author":"Administration UF and D"},{"key":"10.1016\/j.yebeh.2020.107261_bb0135","author":"Administration UF and D"},{"key":"10.1016\/j.yebeh.2020.107261_bb0140","unstructured":"Prevention C for DC and. Drug overdose deaths n.d. https:\/\/www.cdc.gov\/drugoverdose\/data\/statedeaths.html (accessed January 30, 2020)."},{"key":"10.1016\/j.yebeh.2020.107261_bb0145","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/pds.4278","article-title":"National trends in long-term use of prescription opioids","volume":"27","author":"Mojtabai","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.yebeh.2020.107261_bb0150","first-page":"849","article-title":"Comorbidity in adults with epilepsy \u2014 United States, 2010","volume":"62","author":"Kadima","year":"2013","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.yebeh.2020.107261_bb0155","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1360-0443.2011.03563.x","article-title":"Benzodiazepines revisited\u2014will we ever learn?","volume":"106","author":"Lader","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.yebeh.2020.107261_bb0160","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","article-title":"Benzodiazepine use in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiat"},{"key":"10.1016\/j.yebeh.2020.107261_bb0165","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1176\/appi.ps.201800321","article-title":"Benzodiazepine use and misuse among adults in the United States","volume":"70","author":"Maust","year":"2019","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.yebeh.2020.107261_bb0170","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1212\/CON.0000000000000268","article-title":"Management of epilepsy comorbidities","volume":"22","author":"Sirven","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.yebeh.2020.107261_bb0175","article-title":"Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis","volume":"356","author":"Sun","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.yebeh.2020.107261_bb0180","first-page":"85","article-title":"Cohort study of the impact of high-dose opioid analgesics on overdose mortality","volume":"17","author":"Dasgupta","year":"2016","journal-title":"Pain Med (United States)"},{"key":"10.1016\/j.yebeh.2020.107261_bb0185","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/cap.2013.0036","article-title":"Side effects from use of one or more psychiatric medications in a population-based sample of children and adolescents","volume":"24","author":"Hilt","year":"2014","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.yebeh.2020.107261_bb0190","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/2211556005666160916124719","article-title":"Psychiatric polypharmacy, etiology and potential consequences","volume":"6","author":"Sarkar","year":"2016","journal-title":"Curr Psychopharmacol"},{"key":"10.1016\/j.yebeh.2020.107261_bb0195","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2020.107261_bb0200","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.yebeh.2009.03.016","article-title":"Epilepsy treatment as a predeterminant of psychosocial ill health","volume":"15","author":"Perucca","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107261_bb0205","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ncl.2009.06.003","article-title":"Determinants of quality of life in people with epilepsy","volume":"27","author":"Jacoby","year":"2009","journal-title":"Neurol Clin"},{"key":"10.1016\/j.yebeh.2020.107261_bb0210","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1212\/WNL.58.8_suppl_5.S9","article-title":"Optimizing health outcomes in active epilepsy","volume":"58","author":"Gilliam","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2020.107261_bb0215","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.yebeh.2017.11.006","article-title":"Quality of life in adults with epilepsy is associated with anticonvulsant polypharmacy independent of seizure status","volume":"78","author":"Alexander","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107261_bb0220","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2020.107261_bb0225","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/epi.12305","article-title":"Withdrawal of antiepileptic drugs: guidelines of the Italian League Against Epilepsy","volume":"54","author":"Beghi","year":"2013","journal-title":"Epilelpsia"},{"key":"10.1016\/j.yebeh.2020.107261_bb0230","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.yebeh.2007.01.014","article-title":"Slight improvement in mood and irritability after antiepileptic drug withdrawal: a controlled study in patients on monotherapy","volume":"10","author":"Hessen","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107261_bb0235","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1600-0404.2008.01109.x","article-title":"Antiepileptic monotherapy significantly impairs normative scores on common tests of executive functions","volume":"119","author":"Hessen","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2020.107261_bb0240","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ana.24427","article-title":"Intelligence quotient improves after antiepileptic drug withdrawal following pediatric epilepsy surgery","volume":"78","author":"Boshuisen","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2020.107261_bb0245","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.seizure.2016.02.001","article-title":"The effect of quantitative and qualitative antiepileptic drug changes on cognitive recovery after epilepsy surgery","volume":"36","author":"Helmstaedter","year":"2016","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.107261_bb0250","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1528-1157.1992.tb01769.x","article-title":"Psychosocial outcomes of antiepileptic drug discontinuation. The Medical Research Council Antiepileptic Drug Withdrawal Study Group","volume":"33","author":"Jacoby","year":"1992","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107261_bb0255","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2471\/BLT.09.064147","article-title":"Global disparities in the epilepsy treatment gap: a systematic review","volume":"88","author":"Meyer","year":"2010","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.yebeh.2020.107261_bb0260","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.yebeh.2011.11.002","article-title":"Validation of self-reported epilepsy for purposes of community surveillance","volume":"23","author":"Brooks","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107261_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/dis.2005.8.1","article-title":"Developing a computer algorithm to identify epilepsy cases in managed care organizations","volume":"8","author":"Holden","year":"2005","journal-title":"Dis Manag"},{"key":"10.1016\/j.yebeh.2020.107261_bb0270","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/AJP.0000000000000248","article-title":"Accuracy of self-reported prescribed analgesic medication use Quebec administrative prescription claims databases","volume":"32","author":"Lacasse","year":"2016","journal-title":"Clin J Pain"},{"key":"10.1016\/j.yebeh.2020.107261_bb0275","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.genhosppsych.2010.03.006","article-title":"The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review","volume":"32","author":"Kroenke","year":"2010","journal-title":"Gen Hosp Psychiatry"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020304406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020304406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:35:06Z","timestamp":1761503706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505020304406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":55,"alternative-id":["S1525505020304406"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107261","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polypharmacy in patients with epilepsy: A nationally representative cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107261","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107261"}}